Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Zydus Lifesciences receives USFDA warning letter for Baddi facility
Zydus Lifesciences said the USFDA has issued a warning letter for its Baddi manufacturing facility over observations related to purified talc specifications. The company said the communication does not relate to an on-site inspection and is not expected to impact operations or supplies.
Zydus Lifesciences slips after Baddi units receives warning letter from US FDA
Zydus Lifesciences fell 2.24% to Rs 1053.10 after the company said that it has received a warning letter from the United States Food and Drug Administration (USFDA) relating to its formulation manufacturing facility located at Baddi, Himachal Pradesh
Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns
The Delhi High Court has asked the Central Drugs Standard Control Organisation to review a petition challenging Zydus Lifesciences' approval for semaglutide injections. A diabetes patient raised concerns about the drug's delivery system, alleging it deviates from global standards and poses health risks. The court has directed the CDSCO to consider the patient's representation within two months.
Zydus Lifesciences share buyback to open on 4 June: Should you participate or not?
Ahead of the buyback opening, Zydus Life stock was trading 2.5% lower at ₹1,063 apiece on Tuesday, 2 June. Here are the buyback details, along with experts' opinions on whether retail investors should participate.
Zydus Lifesciences share buyback opens June 4; Check entitlement ratio and details here
This is the third instance of the company carrying out a share buyback since 2022. The previous one was done back in 2024 at a price of ₹1,005 per share.
Zydus Lifesciences Ltd spurts 1.81%, up for five straight sessions
Zydus Lifesciences Ltd is quoting at Rs 1105.45, up 1.81% on the day as on 12:44 IST on the NSE. The stock is up 18.87% in last one year as compared to a 3.64% fall in NIFTY and a 15.5% fall in the Nifty Pharma.
Zydus Lifesciences up 2% to 52-wk high on USFDA review nod, buyback tweak
The pharmaceutical company said the buyback price has been increased from ₹1,150 per equity share to ₹1,260 per equity share
Stocks to Watch for May 29: Zydus Life, Patanjali, RIL, Swiggy, Godfrey Phillips and more
From Zydus Lifesciences raising its buyback price and Reliance Industries announcing its AGM and dividend record date, to PhysicsWallah sharply narrowing Q4 losses on strong revenue growth, here are the stocks to watch ahead of Friday’s trading session.
Zydus Lifesciences raises share buyback price, cuts share count. Details here
Zydus Lifesciences announced an increase in its share buyback pricebut a cut in the number of shares offered. Here's the new buyback price, along with other revised details of the offer.
Zydus Lifesciences hikes share buyback price to Rs 1,260 per share, lowers share count
Zydus Lifesciences increased its share buyback price to Rs 1,260 per share while reducing the repurchase size to 87.3 lakh shares. The total buyback outlay remains Rs 1,100 crore. The pharma stock has outperformed benchmark indices over the past one year with a 19% rally.
Zydus Lifesciences Reduces Buyback Size — Check Revised Price
Promoters will also participate in the buyback, with May 29, 2026, fixed as the record date for determining the shareholder eligibility.
Zydus Life hikes buyback price to ₹1,260; cuts size to 87.30 lakh equity shares
The buyback price has been increased from ₹1,150/share to ₹1,260; the maximum number of equity shares proposed to be bought back has been reduced from 95.65 lakh to 87.30 lakh. Shares of Zydus Lifesciences Ltd ended at ₹1,085.95, up by ₹7, or 0.65%, on the BSE today, May 27.